Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer

Damodaran, Srinivasan; Bellavia, Tanya; Sait, Sheila N.J.; Wang, Eunice S.; Wetzler, Meir

doi:10.1016/j.clcc.2011.09.002

Cited by 7 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, many chemotherapy treatments such as Oxaliplatin and Capecitabine have been shown to cause TRML, which are important in neoadjuvant therapy in cases of CRC and even gastrointestinal malignancies. Many reported cases have shown that Oxaliplatin may cause TRML with an initial presentation of pancytopenia, petechiae, or ecchymoses, which was similar to our patient [6,[10][11][12]. Such cases can present with rapid deterioration and complication such as DIC and associated hyperfibrinolysis, which can lead to severe hemorrhagic outcomes [6].…”

Section: Discussionsupporting

confidence: 77%

“…Moreover, mutations of chromosome 5 and 7 are frequently seen involved after Oxaliplatin therapy and a reason is yet unclear to the cause of such mutation [ 12 ]. However, Capecitabine works in a similar pattern, which is a DNA destructive pattern with intra- and inter-strand DNA cross links with leukemogenicity characteristics, where it disrupts replication and transcription of the DNA leading to apoptosis [ 11 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rectal Cancer Complicated by Acute Promyelocytic Leukemia

Alkhayyat

2020

Cureus

View full text Add to dashboard Cite

Globally colorectal cancer is one of the leading causes of mortality among men. Treatment modalities of chemotherapy and radiotherapy may put a risk in developing therapy related myeloid leukemia (TRML). TRML has been reported with Oxaliplatin, Capecitabine, and radiation therapy, which may consequently lead to DNA damage, causing a secondary disease. Acute Promyelocytic Leukemia (APL) is a type of TRML that occurs as a result of such therapies. We present a case of a 30 year old male who presented as a case of colorectal cancer. Subsequently, the patient received Capecitabine with radiotherapy followed by abdominoperineal resection. He received four additional cycles of XELOX protocol of chemotherapy. Months later, he returned with an intestinal obstruction and a picture of TRML. After a bone marrow biopsy, fluorescence in situ hybridization (FISH) and cytogenetics evaluation, the diagnosis of APL was confirmed. All-trans retinoic acid (ATRA) therapy was initiated with excellent response. In conclusion, TRML in the form of APL needs to be diagnosed early and treated as a medical emergency to prevent the high mortality rate associated with the disease.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Rectal Cancer Complicated by Acute Promyelocytic Leukemia

Alkhayyat

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…These clinical manifestations have featured both types of t-MN. The clinical characteristics of 8 patients who developed TRL after treatment with OXP are summarized in table 1 [7, 8, 9, 10, 11, 12, 13]. There were 5 male and 3 female patients with a mean age of 64 years (range, 25–79).…”

Section: Discussionmentioning

confidence: 99%

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

et al. 2014

View full text Add to dashboard Cite

Therapy-related leukemia (TRL) has been reported to occur after treatment with alkylating agents and/or topoisomerase II inhibitors. Oxaliplatin (OXP) is used as a key drug for the treatment of colorectal cancer (CRC). Cisplatin and carboplatin have been linked with TRL, but the involvement of OXP is questionable. A 74-year-old male was diagnosed with peritoneal metastasis from CRC in July 2011. The patient received nine cycles of 5-fluorouracil (5-FU), leucovorin (LV), and OXP (mFOLFOX-6 regimen) and three cycles of 5-FU and LV only, resulting in a clinical complete response. However, recurrence of CRC was detected by CT within 3 months after the last course of chemotherapy. In April 2013, laboratory tests showed pancytopenia and 15% blast cells. A bone marrow examination revealed multilineage dysplasia and 20.4% myeloblasts. Cytogenetic analysis indicated a complex karyotype that included chromosome 5 and 7 abnormalities. The patient was diagnosed with TRL and treated with a combination of azacitidine (AZA) and cetuximab (Cmab) for both cancers. AZA might be useful in TRL when a patient needs to be treated simultaneously for more than one primary cancer because of its low toxicity. Moreover, Cmab is an effective therapeutic tool in TRL patients with metastatic CRC with the wild-type K-ras gene.

show abstract

“…Generally, the most frequent adverse effects of capecitabine are hyperbilirubinemia, diarrhea, nausea, hand-foot syndrome, and dermatitis. Hematological side effects of capecitabine including anemia, lymphopenia, neutropenia, and thrombocytopenia is well-known (2), however the leukemogenic effect of capecitabine was rarely reported (3)(4)(5)(6)(7). Here we present a patient with metastatic breast cancer and therapy related acute myeloblastic leukemia after capecitabine treatment.…”

Section: Introductionmentioning

confidence: 96%

Capecitabine Induced Therapy Related Acute Myeloblastic Leukemia with t(10;11) (q22;q23) in a Patient with Breast Cancer

2018

GMJ

View full text Add to dashboard Cite

Capecitabine is an oral agent that is used either as single agent or in combination therapy. Therapy related acute myeloblastic leukemia after capecitabine use is rarely reported. We presented a 39-year-old woman with metastatic breast cancer. She admitted with acute myelomonocytic leukemia after treating with oral Capecitabine. t(10;11)(q22;q23) was determined in conventional cytogenetic analysis. She achieved complete remission with intensive chemotherapy but relapse developed. She died although the salvage chemotherapy. To our knowledge our patients is the first report with t-AML with t(10;11)(q22;q23) secondary to Capecitabine use for breast cancer treatment. Capecitabine should be carefully used especially in patients with high risk for t-AML.Key Words: Capecitabine, therapy related acute myeloblastic leukemia, breast cancer, t(10;11)(q22;q23) Received: 01.24.2017Accepted: 10.07.2017 ÖZETCapesitabin tek başına veya kombinasyon tedavileri ile kullanılabilen ve oral yolla kullanılan bir tedavi ajanıdır. Capesitabin kullanımı ile ilişkilendirilen tedavi ilişkili lösemi olguları oldukça nadirdir. Biz 39 yaşında metastatic meme kanserli bir olguyu sunduk. Hasta Capesitabin ile tedavi edildikten sonra akut myelomonositik lösemi ile başvurdu. t(10;11)(q22;q23) konvansiyonel sitogenetik çalışmada saptandı. İndüksiyon kemoterapi ile remisyon sağlanmasına karşın daha sonra relaps gelişti. Kurtarma kemoterapi verildi, ancak hasta kaybedildi. Bu vaka Capesitabin kullanımı sonrası t(10;11)(q22;q23) ile birlikte t-AML geliştiğini gösteren ilk rapordur. T-AML gelişimi yüksek hastalar Capesitabin kullanımı sırasında yakından izlenmelidir.Anahtar Sözcükler: Capesitabin, tedavi ilişkili akut myeloblastik lösemi, meme kanseri, t(10;11)(q22;q23)

show abstract

Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer

Cited by 7 publications

References 19 publications

Rectal Cancer Complicated by Acute Promyelocytic Leukemia

Rectal Cancer Complicated by Acute Promyelocytic Leukemia

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

Capecitabine Induced Therapy Related Acute Myeloblastic Leukemia with t(10;11) (q22;q23) in a Patient with Breast Cancer

Contact Info

Product

Resources

About